Show simple item record

dc.contributor.authorMorales Painamil, Rodrigo Alfredo
dc.contributor.authorGonzález de Aledo-Castillo, José Manuel
dc.contributor.authorTeresa-Palacio, Marta
dc.contributor.authorArgudo-Ramírez, Ana
dc.contributor.authorLópez-Galera, Rosa M.
dc.contributor.authorParedes-Fuentes, Abraham Jose
dc.contributor.authorAldecoa-Bilbao, Victoria
dc.contributor.authorAlsina, Miguel
dc.date.accessioned2024-06-03T15:48:02Z
dc.date.available2024-06-03T15:48:02Z
dc.date.issued2023
dc.identifier.citationMorales Painamil, Rodrigo Alfredo; González de Aledo-Castillo, José Manuel; Teresa-Palacio, Marta [et al.]. Foetal haemoglobin as a marker of bone marrow suppression secondary to anti-kell alloimmunisation. International Journal of Neonatal Screening, 2023, 9(2), 24. Disponible en: <https://www.mdpi.com/2409-515X/9/2/24>. Fecha de acceso: 3 jun. 2024. DOI: 10.3390/ijns9020024ca
dc.identifier.issn2409-515Xca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/4259
dc.description.abstractAnti-Kell alloimmunisation is a potentially severe minor blood group type incompatibility, not only as a cause of haemolytic disease of the foetus and newborn, but also due to the destruction of red blood cells (RBC) and mature form in the bone marrow with the subsequent hyporegenerative anaemia. In severe cases and when the foetus shows signs of anaemia, an intrauterine transfusion (IUT) may be necessary. When repeated, this treatment can suppress erythropoiesis and worsen the anaemia. We report the case of a newborn who required four IUTs plus an additional RBC transfusion at one month of life due to late onset anaemia. The identification of an adult haemoglobin profile with a complete absence of foetal haemoglobin in the patient’s newborn screening samples at 2 and 10 days of life warned us of a possible late anaemia. The newborn was successfully treated with transfusion, oral supplements and subcutaneous erythropoietin. A blood sample taken at 4 months of life showed the expected haemoglobin profile for that age with a foetal haemoglobin of 17.7%. This case illustrates the importance of a close follow-up of these patients, as well as the usefulness of the haemoglobin profile screening as a tool for anaemia assessment.ca
dc.format.extent6ca
dc.language.isoengca
dc.publisherMDPIca
dc.relation.ispartofInternational Journal of Neonatal Screeningca
dc.relation.ispartofseries9;2
dc.rights© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).ca
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.otherTransfusióca
dc.subject.otherEritropoietinaca
dc.subject.otherMalaltia hemolítica del nounatca
dc.subject.otherDeterminació de Kellca
dc.subject.otherSang incompatibilitat de grupca
dc.subject.otherTransfusiónca
dc.subject.otherEritropoyetinaca
dc.subject.otherEnfermedad hemolítica del recién nacidoca
dc.subject.otherDeterminación de Kellca
dc.subject.otherSangre incompatibilidad de grupoca
dc.subject.otherTransfusionca
dc.subject.otherErythropoietinca
dc.subject.otherHemolytic disease of the newbornca
dc.subject.otherKell determinationca
dc.subject.otherBlood group incompatibilityca
dc.titleFoetal haemoglobin as a marker of bone marrow suppression secondary to anti-kell alloimmunisationca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.identifier.doihttps://dx.doi.org/10.3390/ijns9020024ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint